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http://www.darujps.com/content/22/1/83RESEARCH ARTICLE Open AccessDesign, synthesis, docking study and cytotoxic
activity evaluation of some novel letrozole analogs
Mohsen Vosooghi1, Loghman Firoozpour2, Abolfazl Rodaki2, Mahboobeh Pordeli3, Maliheh Safavi4,
Sussan K Ardestani3, Armin Dadgar1, Ali Asadipour5, Mohammad Hassan Moshafi5 and Alireza Foroumadi5,6*Background: Breast cancer is the most common type of female cancer. One class of hormonal therapy for breast
cancer drugs -non steroidal aromatase inhibitors- are triazole analogues. In this work, some derivatives of these
drugs was designed and synthesized. All synthesized compounds were evaluated for their cytotoxic activities on
breast cancer cell lines (MDA-MB-231, T47D and MCF-7).
Methods: Our synthetic route for designed compounds started from 4-bromotolunitrile which was reacted with
1H-1,2,4-triazole to afford 4-(4-cyanobenzyl)-1,2,4-triazole. The reaction of later compound with aromatic aldehydes
led to formation of the designed compounds. Eleven novel derivatives 1a-k were tested for their cytotoxic activities
on three human breast cancer cell lines.
Results: Among the synthesized compound, 4-[2-(3-chlorophenyl)-1-(1H-1,2,4-triazol-1-yl)ethenyl]benzonitrile (1c)
showed the highest activity against MCF-7 and MDA-MB-231 cell lines and 4-[2-(4-methoxyphenyl)-1-(1H-1,2,4-triazol-
1-yl)ethenyl]benzonitrile (1 h) exhibited highest activity against T47D cell line. According to cytotoxic activities results,
compound 4-[2-(4-dimethylamino)-1-(1H-1,2,4-triazol-1-yl)ethenyl]benzonitrile (1 k) showed comparative activity
against T47D and MDA-MB-231 cell lines with compound (1 h) and our reference drug Etoposide.
Conclusion: In the process of anti-cancer drug discovery, to find new potential anti-breast cancer agents, we designed
and synthesized a novel series of letrozole analogs. Cytotoxicity evaluation revealed that compounds (1c) and (1 k)
were the most potent compounds with comparative activity with Etoposide. The results revealed that π-π interactions
are responsible for the enzyme inhibitions of compounds (1 c) and (1 k).
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Breast cancer is the most common female cancer. Ac-
cording to the American cancer society’s report about
12% of women in the U.S. will develop some invasive
breast cancer during their lifetime. However breast
cancer treatment has a complicated process and prob-
lems, chemotherapy resistance, surgery and available
anti-tumor drugs side effects make it more difficult to gain
the appropriate treatment regimen; consequently, there is
great demand to introduce new active compounds with
more anticancer activity and less unwanted reaction [1,2].* Correspondence: aforoumadi@yahoo.com
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unless otherwise stated.There is some different type of systemic therapy for
breast cancer, one kind is hormonal therapy. Hormonal
therapy can be given to women whose breast cancers test
positive for estrogen to lower estrogen levels. Letrozole is
a third generation of non-steroidal aromatase inhibitor –
one class of hormonal therapy drugs- that was first intro-
duces by Novartis to the market as Femara® for the
treatment of local or metastatic breast cancer [3-5].
Non-steroidal aromatase inhibitors (as shown in Figure 1)
are triazole or imidazole analogues that bind to the active
site of enzyme by coordinating the heme iron atom of
active site through a heterocyclic nitrogen lone pair [5,6].
As it shown in Figure 1, 1-benzyl-1H-1,2,4-triazole scaf-
fold is a conservative section of aromatase inhibitors which
contains various moieties attached to the aliphatic carbon
part of this scaffold. In continuation of our research pro-
gram to find a novel anticancer agent [7-11], and consider-
ing the above mentioned data, in the current study, weral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain





















Figure 1 Structure of non-steroidal aromatase inhibitors.
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http://www.darujps.com/content/22/1/83report the synthesis of a novel series of substituted ethe-
nylbenzene derivatives which linked to1-benzyl-1H-1,2,4-
triazole (1a-k) and evaluated against three human breast
cancer cell lines (Scheme 1).
Methods
Chemistry
All raw-materials, solvents and reagents were provided
from Aldrich Chemicals and Merck AG. A Kofler hot stage
apparatus was used for determination of melting points.
The IR and 1HNMR Spectra were determined on a
Shimadzu 470 (potassium bromide disks) and a Bruker 500
spectrophotometer respectively. Tetramethylsilane (TMS)
was used as internal standard and chemical shifts are re-
ported in ppm relative to it. The elemental analysis for C,
H and N were taken by a Perkin-Elmer 843 spectrometer
with using KBr as diluent. Electrospray ionization mass
spectra (ESI-MS) were recorded by using Agilent 6410
Triple Quad. LC/MS.
Key intermediate 4-(4-cyanobenzyl)-1,2,4-triazole was
prepared according to Doiron J. and his collogues report
[12].
General procedure for preparing of 4[2-aryl-1-(1H-1, 2,
4-triazol-1-yl)ethenyl]benzonitrile (1a-k)
4-(4-Cyanobenzyl)-1,2,4-triazole (1Gr) and 1,4-Dioxane
(10 mL) were added to the reaction vessel and stirred.
Sodium hydride (0.27 Gr 60%) was added to the reaction
mixture in 0–5°C and stirred for 30 minutes. Corre-
sponding aldehyde (0.5 mmol) was added to the mixture
and stirred at room temperature for 30 minutes. Ethanol










Scheme 1 The Synthesis rout of 4-[2-aryl-1-(1H-1,2,4-triazol-1-yl)ethenyl] bestirred for an hour. Reaction mixture cooled to room
temperature and mixture of ice-water (25 Gr) was
added. Precipitate was filtered and recrystallized in etha-
nol to yield corresponding compound (1a-k).
4-[2-Phenyl-1-(1H-1, 2, 4-triazol-1-yl)ethenyl]benzonitrile (1a)
Yield: 73%, mp 141–146°C. IR (KBr, cm−1) νmax: 2245
(nitrile), 1630 (C = C). 1H NMR (500 MHz, CDCl3): δ
8.25(s, 1H, triazole), 8.05 (s, 1H, triazole), 7.70-7.68 (d,
J = 8.55 Hz,2H, benzonitrile), 7.35-7.33 (d, J = 8.55 Hz, 2H,
benzonitrile), 7.30-7.26 (m, phenyl and ethenyl), 6.88-6.87
(d, J = 7.3 Hz, 1H, phenyl), ESI-Mass m/z: 272 [M]+.
4-[2-(2-Chlorophenyl)-1-(1H-1,2,4-triazol-1-yl)ethenyl]
benzonitrile (1b)
Yield: 70%, mp 141–144°C. IR (KBr, cm−1) νmax: 2240 (ni-
trile), 1622 (C =C). 1H NMR (500 MHz, CDCl3): δ 8.16(s,
1H, triazole), 7.96 (s, 1H, triazole), 7.72-7.71 (d , J = 8.45 Hz,
2H, benzonitrile), 7.43 (s, 1H, ethenyl), 7.45 (d, J = 7.75 Hz,
1H, phenyl), 7.40-7.39 (d, J = 8.45 Hz, 2H, benzonitrile),
7.27-7.23 (t, J = 7.9 Hz, 1H, phenyl), 7.08-7.05 (t, J = J =
7.15 Hz, 1H, phenyl), 6.61-6.59 (d, J = 7.75 Hz, 1H, phenyl),
ESI-Mass m/z: 306 [M]+.
4-[2-(3-Chlorophenyl)-1-(1H-1,2,4-triazol-1-yl)ethenyl]
benzonitrile (1c)
Yield: 74%, mp 137–140°C. IR (KBr, cm−1) νmax: 2242 (ni-
trile), 1631 (C = C).1H NMR (500 MHz, CDCl3): δ 8.25(s,
1H, triazole), 8.04 (s, 1H, triazole), 7.70-7.69 (d, J = 8.5 Hz,
2H, benzonitrile), 7.35-7.33 (d, J = 8.5 Hz, 2H, benzoni-
trile), 7.29-7.26 (m, 1H, phenyl), 7.22 (s, 1H, phenyl),









nzonitriles 1a-k. (a) MeOH, KOH, DMF, (b) 1,4-Dioxane, recrystallized in EtOH.
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Yield: 71%, mp 139–146°C. IR (KBr, cm−1) νmax: 2237 (ni-
trile), 1630 (C =C).1H NMR (500 MHz, CDCl3) δ 8.25(s,
1H, triazole), 8.04 (s, 1H, triazole), 7.70-7.69 (d, J =
8.86 Hz,2H, benzonitrile), 7.34-7.33 (d, J = 8.6 Hz, 2H, ben-
zonitrile), 7.27-7.25 (d, J = 8.5 Hz, 2H, phenyl),7.24 (s, 1H,




Yield: 74%, mp 150–153°C. IR (KBr, cm−1) νmax: 2248
(nitrile), 1629 (C = C).1H NMR (500 MHz, CDCl3): δ 8.16
(s, 1H, triazole), 7.96 (s, 1H, triazole), 7.74-7.72 (d, J =
8.35 Hz, 2H, benzonitrile) , 7.42-7.40 (m, 4H, benzonitrile
and ethenyl), 7.04-7.01 (m, 1H, phenyl), 6.56-6.55 (m, 1H,
phenyl), ESI-Mass m/z: 340 [M]+.
4-[2-(3-Fluorophenyl)-1-(1H-1,2,4-triazol-1-yl)ethenyl]
benzonitrile (1f)
Yield: 74%, mp 145–150°C. IR (KBr, cm−1) νmax: 2244
(nitrile), 1634 (C = C).1H NMR (500 MHz, CDCl3): δ 8.25
(s, 1H, triazole), 8.05 (s, 1H, triazole), 7.71-7.69 (d, J =
8.5 Hz,2H, benzonitrile), 7.35-7.33 (d, J = 8.5 Hz, 2H, ben-
zonitrile), 7.30-7.26 (m, 1H, phenyl), 7.25 (s, 1H, ethenyl),
7.03-6.99 (m, 1H, phenyl), 6.68-6.66 (d, J = 7.75 Hz, 1H,




Yield: 74%, mp 128–132°C. IR (KBr, cm−1) νmax: 2242
(nitrile), 1631 (C = C).1H NMR (500 MHz, CDCl3): δ 8.24
(s, 1H, triazole), 8.05 (s,1H, triazole), 7.69-7.67 (d, J =
8.1 Hz, 2H, benzonitrile), 7.34-7.33 (d, J = 8.1 Hz, 2H,
benzonitrile), 7.27 (s, 1H, ethenyl), 7.21-7.18 (t, J = 7.9 Hz,
1H, phenyl), 6.86-6.84 (d, J = 7.6 Hz, phenyl), 6.54-6.53 (d,
J = 7.43 Hz, phenyl), 6.31 (s, 1H, phenyl), 3.66 (s,3H,OMe),
ESI-Mass m/z: 302 [M]+.
4-[2-(4-Methoxyphenyl)-1-(1H-1,2,4-triazol-1-yl)ethenyl]
benzonitrile (1 h)
Yield: 74%, mp 140–143°C. IR (KBr, cm−1) νmax: 2244
(nitrile), 1632 (C = C).1H NMR (500 MHz, CDCl3) δ 8.27
(s, 1H, triazole), 8.08 (s,1H, triazole), 7.67-7.65 (d, J =
8.7 Hz,2H, benzonitrile) , 7.30-7.29 (d , J = 8.7 Hz, 2H,
benzonitrile), 7.25 (s, 1H, ethenyl), 6.80-6.78 (d, J = 9.2 Hz,
2H, phenyl), 6.77-6.76 (d, J = 9.2 Hz, 2H, phenyl), 3.80
(s,3H, OMe), ESI-Mass m/z: 302 [M]+.4-[2-(2,4-Dimethoxyphenyl)-1-(1H-1,2,4-triazol-1-yl)ethenyl]
benzonitrile (1i)
Yield: 74%, mp 158–161°C. IR (KBr, cm−1) νmax: 2239
(nitrile), 1632 (C =C). 1H NMR (500 MHz, CDCl3): δ 8.22
(s, 1H, triazole), 8.06 (s,1H, triazole), 7.66-7.65 (d, J =
8.3 Hz,2H, benzonitrile), 7.50 (s, 1H, ethenyl ), 7.31-7.30 (d,
J = 8.3 Hz, 2H, benzonitrile), 6.44-6.27 (m, 3H, phenyl), 3.84
(s,3H, OMe), 3.79 (s,3H, OMe), ESI-Mass m/z: 332 [M]+.
4-[2-(2,3,4-Trimethoxy)-1-(1H-1,2,4-triazol-1-yl)ethenyl]
benzonitrile (1j)
Yield: 75%, mp 188–191°C. IR (KBr, cm−1) νmax: 2246
(nitrile), 1634 (C = C).1H NMR (500 MHz, CDCl3): δ 8.20
(s, 1H, triazole), 8.09 (s,1H, triazole), 7.67-7.65 (d, J =
8.3 Hz,2H, benzonitrile), 7.51 (s, 1H, ethenyl ), 7.33-7.30 (d,
J = 8.3 Hz, 2H, benzonitrile), 6.46-6.25 (m, 2H, phenyl), 3.86
(s,3H, OMe), 3.81 (s,3H, OMe), 3.76 (s,3H, OMe), ESI-
Mass m/z: 3362 [M]+.
4-[2-(4-Dimethylamino)-1-(1H-1,2,4-triazol-1-yl)ethenyl]
benzonitrile (1 k)
Yield: 72%, mp 158–161°C. IR (KBr, cm−1) νmax: 2241
(nitrile), 1633 (C = C).1H NMR (500 MHz, CDCl3) δ 8.26
(s, 1H, triazole), 8.05 (s,1H, triazole), 7.66-7.65 (d, J =
8.5 Hz,2H, benzonitrile), 7.32-7.27 (d, J = 8.5 Hz, 2H, ben-
zonitrile), 7.25 (s, 1H, ethenyl), 6.79-6.75 (d, J = 9.1 Hz, 2H,
phenyl), 6.74-6.72 (d, J = 9.1 Hz, 2H, phenyl), 3.79-3.75
(m,6H, Me), ESI-Mass m/z: 315 [M]+.
Physicochemical prediction
Marvin was used for chemical drawing, displaying and
characterizing chemical structures, calculator plugins
were used for structure property prediction and calcula-
tion, (version: Marvin 6.0.3, 2013, ChemAxon scientific
package, http://www.chemaxon.com).
Molecular modeling study
Docking studies for selected compounds were performed
using Autodock Vina (ver. 1.1.1) [13]. The crystal structure
of human placental aromatase cytochrome P450 in com-
plex with androstenedione (code ID: 3EQM, resolution [Å]:
2.90) was retrieved from protein data bank [14-17]. Crystal
structure was cleaned from Co-crystallized ligand and
water molecules and the protein was converted to pdbqt
format using Autodock Tools (1.5.4) [18]. 2Dstructures of
ligands converted to 3D in pdbqt format by Openbabel
(ver. 2.3.1) [18]. The docking parameters were set on vina
docking parameter as follow: center_x = 85.027; center_y =
54.737; center_z = 46.428; size_x =50; size_y =50; size_z =50;.
The other parameters were left as default for the program.
Finally, the conformation for the best free energy of
binding was selected for analyzing the interactions be-
tween the macromolecule and selected inhibitors. 3D
Table 1 Target structures and physicochemical properties
No. Comp. Code Ar MW Formula Vander WaalsSurface Polar Surface Log P
1. 1a 272 C17H12N4 363.21 54.50 3.12
2. 1b 306.75 C17H11ClN4 376.65 54.50 3.72
3. 1c 306.75 C17H11ClN4 378.12 54.50 3.72
4. 1d 306.75 C17H11ClN4 378.12 54.50 3.72
5. 1e 341.19 C17H10Cl2N4 393.15 54.50 4.33
6. 1f 290.29 C17H11FN4 369.04 54.50 3.22
7. 1g 302.33 C18H14ON4 410.22 63.73 2.96
8. 1h 302.33 C18H14ON4 409.36 63.73 2.96
9. 1i 332.36 C19H16O2N4 457.69 72.96 2.80
10. 1j 362.38 C20H18O3N4 504.76 82.19 2.65
11. 1k 315.37 C19H17N5 448.10 57.74 3.23
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using the Autodock Tools (1.5.4) [19].
Biological assay
Cell lines and cell culture
Three human breast cancer cell lines including MDA-MB-
231, MCF-7 and T-47D were obtained from National Cell
Bank of Iran (NCBI, Iran). The cells were grown in RPMI-1640 medium supplemented with 10% heat-inactivated
fetal calf serum (GibcoeBRL, UK), 100 mg/ml strepto-
mycin and 100 U/ml penicillin at 37°C/95% rh/5% CO2.
In vitro cytotoxicity assay
The in-vitro cytotoxic activity of all synthesized com-
pounds 1a-k was achieved against three human breast
cancer cell lines using MTT colorimetric assay according
Table 2 In vitro cytotoxic activity (IC50, μg/ml) of





1. 1a 57.1 ± 2.1 87.5 ± 2.5 64.3 ± 1.9
2. 1b 63.2 ± 2.6 97.3 ± 3.1 77.1 ± 2.8
3. 1c 27.1 ± 1.2 14.5 ± 2.1 76.25 ± 7.0
4. 1d 52.3 ± 2.2 43.3 ± 3.4 83.3 ± 5.2
5. 1e 78.3 ± 5.7 83.3 ± 7.2 92.3 ± 6.2
6. 1f 72.3 ± 5.5 85.3 ± 7.4 87.3 ± 7.5
7. 1 g 40.3 ± 2.8 77.4 ± 6.5 69.4 ± 5.7
8. 1 h 74.6 ± 6.5 82.3 ± 7.4 14.3 ± 1.1
9. 1i 75.3 ± 4.4 89.4 ± 6.1 79.1 ± 7.7
10. 1j 69.3 ± 5.3 45.05 ± 6.2 63.3 ± 6.6
11. 1 k 55.3 ± 5.1 19.7 ± 1.8 16.8 ± 2.1
12. Etoposide 7.9 ± 0.5 11.1 ± 1.1 8 ± 0.8
aThe IC50 values represent an average of three independent experiments
(mean ± SD).
Figure 2 Presentation of compounds (1c) and (1 k) with aromatase en
(a, b) visualization of compound (1c) in enzyme with ribbon and molecula
and molecular surface views.
Vosooghi et al. DARU Journal of Pharmaceutical Sciences 2014, 22:83 Page 5 of 7
http://www.darujps.com/content/22/1/83to the method of Mosman [20]. Cells were seeded in 96-
well plates (Nunc, Denmark) and incubated overnight in
a humidified air atmosphere at 37°C with 5% CO2 to allow
cell attachment. The cells were then incubated for another
48 h with various concentrations of compounds 1a-k. The
final concentration of DMSO in the highest concentration
of the applied compounds was 1%. In each plate, there
were three control wells (cells without test compounds)
and three blank wells (the medium with 1% DMSO) for
cell viability. Etoposide were used as positive controls for
cytotoxicity. After 48 h, the culture medium was removed
and 200 μl phenol red-free medium containing MTT (final
concentration 0.5 mg/mL) was added to wells, followed by
4 h incubation.
After incubation, the culture medium was then re-
placed with 100 μl of DMSO and the absorbance of
each well was measured by using a microplate reader at
492 nm. For each compound, the concentration causing
50% cell growth inhibition (IC50) compared with the
control containing 1% DMSO was calculated from con-
centration response curves by regression analysis.zyme, π-π interactions showed in yellow cylindrical shape.
r surface views; (c, d) binding mode of (1 k) in enzyme with ribbon
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Chemistry
4-Bromotolunitrile was converted to 4-(4-cyanoben-
zyl)-1,2,4-triazole and subsequently to corresponding
product, 4-[2-aryl-1-(1H-1,2,4-triazol-1-yl)ethenyl]ben-
zonitrile (1a-k) according to the procedure presented
in Scheme 1. Chemical structures, molecular formula
and molecular weight of compounds (1a-k) are illustrated
in Table 1. Reaction yields are presented in chemistry
section of methods in this report.
Physicochemical prediction
In order to investigate the physicochemical properties
of products, Vander Waals surface, polar surface and
partition-coefficient (Log P) of compounds (1a-k) were
predicted by Marvin program and are reported in Table 1.
As it shown primary physicochemical criteria were passed
by all designed compounds (1a-k).
Cytotoxic activity
The in vitro cytotoxic activity of 4[2-aryl-1-(1H-1,2,4-triazol-
1-yl)ethenyl]benzonitrile (1a-k), were tested against three
human breast cancer lines including MDA-MB-231, T47D
and MCF-7. The various concentrations of the synthetic
compounds (final concentration 5, 10, 20, 40, 80 and
100 μg/ml) were applied to calculate IC50. The 50%
growth inhibitory concentration (IC50) for products were
calculated and depicted in Table 2.
According to MTT assay results in Table 2, 4-[2-(3-
chlorophenyl)-1-(1H-1,2,4-triazol-1-yl)ethenyl]benzonitrile
(1c) showed the highest activity against MCF-7 and
MDA-MB-231 cell lines with IC50 values of 27.1 ± 1.2 and
14.5 ± 2.1 μg/ml, respectively and 4-[2-(4-methoxyphe-
nyl)-1-(1H-1,2,4-triazol-1-yl)ethenyl]benzonitrile (1 h) ex-
hibited highest activity against T47D cell line with IC50
value of 14.3 ± 1.1 μg/ml. As can be seen in Table 2,
compound 4-[2-(4-dimethylamino)-1-(1H-1,2,4-triazol-1-
yl)ethenyl]benzonitrile (1 k), showed comparative activity
against T47D and MDA-MB-231 cell lines with com-
pound 1 h and Etoposide withIC50 values of 16.8 ± 2.1 and
19.7 ± 1.8 μg/ml, respectively. As it shown in MTT assay
results all other synthesized compound did not show good
activity against tested cell lines.
Docking study
In order to understand the binding mode of active com-
pounds in the active site pocket of aromatase, docking
study was performed using Autodock Vina. To attain this
aim, the potent compounds, 1c and 1 k were docked into
target enzyme. Docking strongly suggested that the π-π
interaction between adjacent phenyl rings and hydropho-
bic moieties in enzyme residues –Tyrosine 424 and Tyro-
sine 361- are effective in activity of biologically active
synthesized compounds. According to Figure 2, selectedcompounds fit in the pocket of aromatase enzyme com-
pletely, however missing the potentially hydrogen bond
between ligands and macromolecule is responsible for
moderate activities of compounds (1c) and (1 k).
Conclusion
In the process of anti-cancer drug discovery, to find new
potential anti-breast cancer agents, we designed and syn-
thesized a novel series of letrozole analogs. Cytotoxicity
evaluation revealed that compounds (1c) and (1 k) were
the most potent compounds with comparative activity
with Etoposide. Physicochemical properties of products
predicted and the binding mode of (1c) and (1 k) were
predicted by docking simulation; the results revealed
that π-π interactions are responsible for the enzyme
inhibitions of compounds (1c) and (1 k).
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